Drugs Made in America Acquisition (DMAAU) Stock Price, News & Analysis

Company Overview

Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.

Key Stats

• Today's Range: $10.10 to $10.11
• 50-Day Range: N/A
• 52-Week Range: $10.00 to $10.82
• Volume: 1,816 shs
• Average Volume: 158,244 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DMAAU Stock Analysis - Frequently Asked Questions

How have DMAAU shares performed this year?

Drugs Made in America Acquisition's stock was trading at $10.00 on January 1st, 2025. Since then, DMAAU shares have increased by 1.1% and is now trading at $10.11.
View the best growth stocks for 2025 here.

When did Drugs Made in America Acquisition IPO?

Drugs Made in America Acquisition (DMAAU) raised $200 million in an initial public offering (IPO) on Tuesday, January 28th 2025. The company issued 20,000,000 shares at a price of $10.00 per share. Clear Street acted as the underwriter for the IPO.

When does Drugs Made in America Acquisition's quiet period expire?

Drugs Made in America Acquisition's quiet period expires on Monday, March 10th. Drugs Made in America Acquisition had issued 20,000,000 shares in its IPO on January 28th. The total size of the offering was $200,000,000 based on an initial share price of $10.00. During Drugs Made in America Acquisition's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Drugs Made in America Acquisition?

Shares of DMAAU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Finance, Insurance, And Real Estate
• Industry: Investment Offices
• Sub-Industry: Trading
• Current Symbol: NASDAQ:DMAAU
• CIK: 2028614
• Web: N/A
• Phone: (954) 870-3104
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A